ClinicalTrials.gg
RecruitingNCT07541768Updated Apr 21, 2026

Training Medical Residents in the Use of the Venous Excess UltraSound (VExUS) Score for Bedside Volume Assessment.

An interventional study of In-person VExUS Training Program and Remote VExUS Training Program in Acute Heart Failure (AHF), Fluid Over-load and Congestion, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Sex
All
01

Study summary

This randomized controlled trial evaluates the effectiveness of two training approaches (in-person versus remote) for teaching medical residents to apply the Venous Excess Ultrasound (VExUS) score for bedside volume assessment in patients with acute heart failure. Resident performance will be compared to that of expert physicians certified in abdominal and duplex sonography.

Read the detailed description

Accurate assessment of volume status is essential in managing acute heart failure but remains challenging in clinical practice. The VExUS score is a validated ultrasound-based tool integrating inferior vena cava diameter and Doppler assessment of hepatic, portal, and intrarenal veins.

This single-center randomized controlled trial compares two training modalities (in-person vs. remote) in medical residents with basic ultrasound skills. Participants will be randomized 1:1 to either training method and compared to a control group of expert physicians.

Primary outcomes include ultrasound image quality assessed using a standardized 100-point score. Secondary outcomes include time to acquisition, VExUS scoring accuracy, self-confidence, and acceptability of training methods.

02

Conditions studied

  • Acute Heart Failure (AHF)
  • Fluid Over-load
  • Congestion
  • Congestion, Venous

Browse trials for

Keywords

  • Vexus
  • Venous Excess Ultrasound
  • Point-of-Care Ultrasound
  • POCUS
  • Ultrasound Training
  • Medical Education
  • Volume Assessment
  • Venous Congestion
  • Duplex Ultrasound
  • Bedside Ultrasound
03

In context

Hyperemia

98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.

This study's planned enrollment of 23 is below the median of 68 across 51 interventional studies indexed under Hyperemia.

Browse Hyperemia studies →

Lead sponsor

Insel Gruppe AG, University Hospital Bern is the lead sponsor of 741 studies on the registry; 180 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical residents in general internal medicine
  • Basic ultrasound skills (POCUS component 1 or ≥200 scans)
  • Working at study site during study period

Exclusion criteria

Exclusion Criteria:

  • SGUM certification in abdominal ultrasound
  • Advanced duplex ultrasound experience
  • Prior vascular/duplex training
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    In-person Training

    1-hour theoretical introduction 3-hour supervised practical ultrasound session Group-based hands-on training with expert coach

    Behavioral: In-person VExUS Training Program

  • Experimental
    Remote Training

    E-learning theoretical module 20 independently performed ultrasound exams Asynchronous expert feedback (phone/email)

    Behavioral: Remote VExUS Training Program

  • Active comparator
    Control (Expert Physicians)

    SGUM-certified physicians performing VExUS examinations

    Other: No intervention

Interventions

  • BehavioralIn-person VExUS Training Program

    In-person training consisting of a 1-hour theoretical introduction followed by a 3-hour supervised hands-on ultrasound training session focusing on acquisition and interpretation of the VExUS score.

  • BehavioralRemote VExUS Training Program

    Remote training consisting of an e-learning module followed by independently performed ultrasound examinations with asynchronous expert feedback (via phone or email).

  • OtherNo intervention

    SGUM-certified physicians performing VExUS examinations as expert reference standard.

06

What researchers measure

Primary outcomes

  1. Ultrasound Image Quality Score

    The primary outcome will be a quality score, adapted from a quality score used in a previous randomized controlled trial which investigated a simulator-based training program for transoesophageal echocardiography.11 The quality score will include items commonly used for assessment of ultrasound quality: angle and depth, overall clarity, visualization of the anatomical structures, focus, doppler gain, scale and baseline resulting in a maximum achievable quality score of 100 points. If multiple images of the predefined views are captured, each image will be rated, and the best rating will be kept to calculate the final score. If a view is missing, 0 point will be awarded for that view. All ultrasound images will be independently assessed by experts for abdominal sonography and use Doppler sonography in their daily clinical practice and are blinded to the role (resident vs. SGUM-certified physician) and training (in-person vs. remote) program of the participants.

    Time frame: From training until 6 months after completion of training

Secondary outcomes

  1. Time for Image Acquisition and Interpretation

    Time required by participants to perform the ultrasound examination and interpret the images during VExUS assessment

    Time frame: From training until 6 months after completion of training

  2. Change in self-confidence in performing VExUS assessment

    Self-reported confidence measured using a Likert-scale questionnaire before and after training

    Time frame: From baseline (before training) to immediately after completion of training

  3. Acceptability of the program (quantitative assessment)

    Acceptability of the program will be assessed using a structured survey with 5-point Likert scale items based on an implementation framework (e.g., Theoretical Domains Framework). Results will be reported as mean scores or median values on a 5-point scale, where higher scores indicate greater acceptability.

    Time frame: Immediately after completion of training and during the outcome assessment period (within 2 months after training)

  4. VEXUS score

    The Venous Excess Ultrasound Score (VExUS) is a semi-quantitative ultrasound-based score used to assess systemic venous congestion by combining inferior vena cava (IVC) diameter and Doppler flow patterns of abdominal veins, including hepatic, portal, and intrarenal veins. The score ranges from 0 to 3, with 0 indicating no congestion, 1 indicating mild congestion, 2 indicating moderate congestion, and 3 indicating severe venous congestion. Higher scores indicate greater venous congestion and worse clinical status.

    Time frame: From training until 6 months after completion of training

  5. Acceptability of the program (qualitative assessment)

    Acceptability, including perceived barriers and facilitators to implementation, will be explored through semi-structured interviews. Data will be analyzed using thematic analysis guided by an implementation framework.

    Time frame: Immediately after completion of training and during the outcome assessment period (within 2 months after training)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 21, 2026
StartActual
Mar 20, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07541768
Responsible party
Claudio Schneider (Senior physician, Insel Gruppe AG, University Hospital Bern) — Principal investigator
First posted
Apr 21, 2026
Start date
Mar 20, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 21, 2026

Study contacts

Caroline Rimensberger, MD
Contact
caroline.rimensberger@insel.ch
0041316322111
Claudio Schneider, MD
Contact
claudio.schneider@insel.ch
0041316322111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion